What Caused Biohaven (BHVN) Shares To Drop More Than 16% After Hours?

Benzinga_recent_news

2025/12/25

Biohaven Ltd. (NYSE:BHVN) shares dropped 16.19% in after-hours trading to $9.06 on Wednesday after the company reported that its Phase 2 depression drug trial missed its primary endpoint. Check out ...

网页链接

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2594428089"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2594428089\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2594428089?lang=zh_CN&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/25/Downward-Red-Business-Chart-On-Blurry-Ba.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2025-12-25 14:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2594428089","market":"us","top_or_hot":-1,"title":"What Caused Biohaven (BHVN) Shares To Drop More Than 16% After Hours?","media":"Benzinga_recent_news","content":"<div>\n<p>Biohaven Ltd. (NYSE:BHVN) shares dropped 16.19% in after-hours trading to $9.06 on Wednesday after the company reported that its Phase 2 depression drug trial missed its primary endpoint.\nCheck out ...</p>\n\n<a href=\"https://www.benzinga.com/markets/equities/25/12/49588814/what-caused-biohaven-bhvn-shares-to-drop-more-than-16-after-hours\">网页链接</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>What Caused Biohaven (BHVN) Shares To Drop More Than 16% After Hours?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhat Caused Biohaven (BHVN) Shares To Drop More Than 16% After Hours?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-25 14:52 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/equities/25/12/49588814/what-caused-biohaven-bhvn-shares-to-drop-more-than-16-after-hours><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biohaven Ltd. (NYSE:BHVN) shares dropped 16.19% in after-hours trading to $9.06 on Wednesday after the company reported that its Phase 2 depression drug trial missed its primary endpoint.\nCheck out ...</p>\n\n<a href=\"https://www.benzinga.com/markets/equities/25/12/49588814/what-caused-biohaven-bhvn-shares-to-drop-more-than-16-after-hours\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RSI","symbol_name":"Rush Street Interactive, Inc.","start_time":0,"source_url":"https://www.benzinga.com/markets/equities/25/12/49588814/what-caused-biohaven-bhvn-shares-to-drop-more-than-16-after-hours","article_id":"2594428089","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/25/Downward-Red-Business-Chart-On-Blurry-Ba.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/25/12/49588814/what-caused-biohaven-bhvn-shares-to-drop-more-than-16-after-hours","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2594428089","pubTimestamp":1766645520,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Biohaven shares fell 16.19% in after-hours trading Wednesday after its Phase 2 depression drug trial missed the primary endpoint.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"RSI":"Rush Street Interactive, Inc.","BK4139":"生物科技","BHVN":"Biohaven Pharmaceutical Holding Co Ltd.","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4150":"赌场与赌博","DVAX":"德纳维制药","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1"},"translate_title":"是什么导致Biohaven(BHVN)股价盘后下跌超过16%？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RSI":1,"BHVN":1.5,"DVAX":1},"content_text":"Biohaven Ltd. (NYSE:BHVN) shares dropped 16.19% in after-hours trading to $9.06 on Wednesday after the company reported that its Phase 2 depression drug trial missed its primary endpoint.\nCheck out the current price of BHVN stock here.\nThe stock closed regular session at $10.81, up 2.95%, according to Benzinga Pro data.\nThe biopharmaceutical company announced BHV-7000, an investigational drug for major depressive disorder, failed to achieve a reduction in depressive symptoms versus placebo in the six-week study, measured by the Montgomery Åsberg Depression Rating Scale.\nAccording to Biohaven, trends favoring BHV-7000 were seen in subgroups with more severe depression at screening and baseline, on both primary and secondary outcome measures.\nSee Also: Dynavax Technologies (DVAX) Shares Are Trending Overnight — Here’s Why\nBHV-7000 was well-tolerated, with mostly mild adverse events. \nHeadache occurred in 10.7% of BHV-7000 patients and 9.9% of placebo patients, while nausea occurred in 4.2% and 5.6%, respectively.\n“The results do not support the efficacy of BHV-7000 in a broad population of depressed patients,” said Dr. Ahmed Tahseen, Development Lead for Depression at Biohaven. \nThe company said it is considering halting psychiatric trials and redirecting resources toward immunology, obesity, and epilepsy in 2026. \nManagement will also present clinical program updates at the J.P. Morgan Healthcare Conference in January, including data on extracellular degrader programs and its Phase 2b obesity study.\nBiohaven has a relative strength index (RSI) of 50.35, a market capitalization of $1.43 billion, and a 52-week trading range of $7.48 to $44.28.\nOver the past 12 months, Biohaven Ltd. has dropped 70.32%, highlighting significant long-term weakness and challenges in regaining momentum.\nCurrently, the stock is trading about 9.1% above its 52-week low, indicating it is near its lows. This positioning suggests a lack of buying interest and potential for further downside.\nBenzinga's Edge Stock Rankings indicates BHVN stock has a negative price trend across all time frames. Here is how the stock fares on other parameters.\nRead Next:\nPhoto Courtesy: Who is Danny on Shutterstock.com\nDisclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}